I don't think remdesivir is widely available outside of a clinical trial, so the NEJM case series probably had a tiny fraction of the effect of Raoult's initial HCQ "study".
-
-
-
True, but stocks still ran very low almost immediately. Both terrible ethically I think
End of conversation
New conversation -
-
-
Will we learn from this though? No. I’m not immune either. I want to know that therapies for this are improving. I suspect anti-virals are a pipe dean though. We should concentrate on preventing death and morbidity by treating the symptoms.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
I felt that the authors wrote the report well. It is ethical to publish a case series, and if there had been an early safety signal that would have been especially useful. The issue is with the media and other portrayals that were overblown.
-
I would've been more sanguine had it not been published by NEJM as a clinical study and presented as a major important finding, rather than the tentative evidence it really was
End of conversation
New conversation -
-
-
I thought that publishing that paper demonstrated very poor judgment on the part of the editors, because it showed so little and met with such fanfare
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
The NIAID-NIH large double blind RCT is rummored to be far enough advanced that early results will be available by mid-May.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.